CClinicalTrials.gg
CompletedNCT07376421Updated May 1, 2026

Clinical Investigation Exploring a Newly Developed Ostomy Baseplate

An interventional study of Incestigational device and Comparator in Stoma Ileostomy, sponsored by Coloplast A/S. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Coloplast A/S · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Peristomal skin complications (PSCs) are the predominant complication for people living with a stoma, which affect their quality of life negatively.

Among the main reasons for developing PSCs are that the peristomal skin is exposed to stomal output either due to leakage of output under the baseplate and/or imperfect cutting of the hole in the baseplate, and incorrect application creating a gap between the hole in the baseplate and the stoma.

To seal this gap, Coloplast has developed a new ostomy baseplate and the aim of the investigation is to explore the investigational device 's ability to help protect the peristomal skin.

02

Conditions studied

  • Stoma Ileostomy
03

In context

Lead sponsor

Coloplast A/S is the lead sponsor of 146 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Has given written consent
  • Is at least 18 years of age
  • Has full legal capacity
  • Has an ileostomy with consistent liquid fecal output (6-7 Bristol scale).
  • Has used flat 1- or 2-piece SenSura Mio, SenSura or Assura Coloplast products for at least 14 days prior to inclusion.
  • Has had the stoma for at least 90 days.
  • Has a stoma size less than 40mm in diameter
  • Has experienced leakage under the baseplate at least three times within the last 14 days.
  • Leakage defined as output/seeping under the baseplate (see Appendix A)
  • Has experienced symptoms of peristomal skin complications such as itching, burning, or pain in the peristomal area within the last 14 days.
  • Has suitable peristomal skin area (assessed by investigator)
  • Is able to handle the electronic diary (questionnaire/photo) themselves. If needed, a trained spouse or caretaker is allowed to assist.
  • Is able to handle (apply, remove, etc.) the investigational devices themselves.
  • Understands that any supporting products under the baseplate are not permissible during the investigation (except for adhesive removers) and is willing to not use these during the investigation.
  • Is willing and suitable (determined by the Principal Investigator or designee) to use a flat 2-piece device during the investigation.
  • Is willing to change the baseplate at least every third/fourth day during the investigation.

Exclusion criteria

Exclusion Criteria:

  • Is currently receiving or have within the past 60 days received radio-and/or chemotherapy.
  • Low doses radio- and/or chemotherapy (assessed by Principal Investigator) is allowed for other indications than cancer.
  • Is currently receiving or have within the past 30 days received topical steroid treatment in the peristomal skin area, e.g., lotion or spray treatment.
  • Is breastfeeding.
  • Is pregnant based on urine pregnancy test.
  • Has known hypersensitivity towards any of the investigational devices used in the investigation.
  • Has a complicated stoma at baseline, as assessed by investigator (e.g., dehiscence/prolapse/hernia).
  • Participates in other clinical investigations. Exception: Participation in other Coloplast sponsored clinical investigations is accepted under the circumstances that the subject has paused the activities in the investigation and is otherwise complying with the inclusion and exclusion criteria of this protocol.
  • Daily use of analgesics, antihistamine or steroid treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Investigational device

    4 weeks treatment with investigational device

    Device: Incestigational device

  • Active comparator
    Comparator

    4 weeks treatment with investigational device

    Device: Comparator

Interventions

  • DeviceIncestigational device

    4 weeks treatment with investigational device

  • DeviceComparator

    4 weeks treatment with comparator

06

What researchers measure

Primary outcomes

  1. Maximum itching scale 0-10)

    Itching score (weekly max at steady state\* scale 0-10). \* To account for a possible carry-over effect, the steady state period of the treatment period begins after two weeks of investigational device or comparator use. It is anticipated that the skin will have adapted to the new device after two weeks.

    Time frame: 8 weeks

07

Study locations

1 site
  • Coloplast A/S
    Humlebæk, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07376421
Lead sponsor
Coloplast A/S
Responsible party
Sponsor
First posted
Jan 29, 2026
Start date
Jan 24, 2026
Primary completion
Apr 9, 2026
Completion
Apr 9, 2026
Last update
May 1, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion